|
TRIAL SEARCH
TCOP conducts a variety of clinical trials every year. In fact,
there are over 100 trials running at any given time, each specifically
focusing on a particular type of cancer research. To find out if there
are current trials running, addressing a specific form of cancer,
click on a cancer type in the list below.
BrainN0776 SUSPENDEDProtocol Document: N0776 SUSPENDED
Protocol Number: N0776 SUSPENDED
Phase II Trial of Avastin in Combination with Sorafenib in Recurrent Glioblastoma Multiforme
Trial Type: Clinical
N0877 Open to Phase 1 Only at this timeProtocol Document: N0877 Open to Phase 1 Only at this time
Protocol Number: N0877 Open to Phase 1 Only at this time
Phase I Randomized Phase II Trial of Either Dasatinib or Placebo Combined with Standar Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme
Trial Type: Clinical
R0825Protocol Document: R0825
Protocol Number: R0825
Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab vs. Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma
Trial Type: Clinical
N0577Protocol Document: N0577
Protocol Number: N0577
Phase III Intergroup Study of Radiotherapy vs. Temozolomide Alone vs. Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma
Trial Type: Clinical
BreastS0221Protocol Document: S0221
Protocol Number: S0221
Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer.
Trial Type: Clinical
893052Protocol Document: 893052
Protocol Number: 893052
Phase III Trial of Adjuvant Therapy with Tamoxifen Alone or combined with Fluoxymesterone in Post-Menopausal Women with Resected Estrogen Receptor Positive Breast Cancer.
Trial Type: Clinical
E2197Protocol Document: E2197
Protocol Number: E2197
Phase III Study of Adriamycin/Taxotere vs. Adriamycin/Cytoxan in Adjuvant Treatment of Node+ and High Rise Node- Breast Cancer
Trial Type: Clinical
E2Z04Protocol Document: E2Z04
Protocol Number: E2Z04
Quality of Life in Younger Breast Cancer Survivors
Trial Type: Clinical
MA.17RProtocol Document: MA.17R
Protocol Number: MA.17R
Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed iwth Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in MA.17 Study)
Trial Type: Clinical
N0336Protocol Document: N0336
Protocol Number: N0336
Phase II Trial of Raf Kinase Inhibitor BAY 43-9006 as Single Oral Agent in Patients with
Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane
Trial Type: Clinical
N063IProtocol Document: N063I
Protocol Number: N063I
Charnges in Breast Density and Plasma Hormone Levels After One Year of Aromatase Inhibitor Therapy
Trial Type: Clinical
S0012Protocol Document: S0012
Protocol Number: S0012
A COMPARATIVE RANDOMIZED STUDY OF STANDARD DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY WEEKLY PACLITAXEL VS. WEEKLY DOXORUBICIN AND DAILY ORAL CYCLOPHOSPHAMIDE PLUS G-CSF FOLLOWED BY WEEKLY PACLITAXEL AS NEOADJUVANT THERAPY FOR INFLAMMATORY AND LOCALLY ADVANCED BREAST CANCER
Trial Type: Clinical
S0226 - Pharmacokinetic component closedProtocol Document: S0226 - Pharmacokinetic component closed
Protocol Number: S0226 - pharmacokinetic component closed
PHASE III RANDOMIZED TRIAL OF ANASTROZOLE VERSUS ANASTROZOLE AND FULVESTRANT AS FIRST LINE THERAPY FOR POST MENOPAUSAL WOMAN WITH METASTATIC BREAST CANCER
Trial Type: Clinical
Z1031 TCOP ClosureProtocol Document: Z1031 TCOP Closure
Protocol Number: Z1031
Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane, Letrozole or Anastrozole in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
Trial Type: Clinical
B-39 BAHO Sub-Study ClosedProtocol Document: B-39 BAHO Sub-Study Closed
Protocol Number: B-39 BAHO Sub-Study Closed
A RANDOMIZED PHASE III STUDY OF CONVENTIONAL WHOLE BREAST IRRADIATION (WBI) VERSUS PARTIAL BREAST IRRADIATION (PBI) FOR WOMEN WITH STAGE 0, I, OR II BREAST CANCER.
Trial Type: Clinical
CALGB 40603Protocol Document: CALGB 40603
Protocol Number: CALGB 40603
Randomized Phase II 2x2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor Poor/HER 2 Negative Resectable Breast Cancer
Trial Type: Clinical
B 43Protocol Document: B 43
Protocol Number: B 43
Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2 Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Trial Type: Clinical
B 44I - call for consentProtocol Document: B 44I - call for consent
Protocol Number: B 44I - call for consent
Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2 Positive Node-Positive or High Risk Node Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
Trial Type: Clinical
N063D Design 2BProtocol Document: N063D Design 2B
Protocol Number: N063D
ALTTO Study. Ajuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study. A Randomized, Multi-Center, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, their sequence and their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
Trial Type: Clinical
N0733 Protocol Document: N0733
Protocol Number: N0733
Randomized Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Patients with HER2+ Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane
Trial Type: Clinical
CALGB 40502 Protocol Document: CALGB 40502
Protocol Number: CALGB 40502
Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound NAB-Paclitaxel or Ixabepilone Combined with Bevacizumab as First-Line therapy for Locally Recurrent or Metastatic Breast Cancer
Trial Type: Clinical
S0500Protocol Document: S0500
Protocol Number: S0500
Randomized Phase III Trial to Test the Strategy of Changing Therapy vs. Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment.
Trial Type: Clinical
C70301 (substudy to C40101)Protocol Document: C70301 (substudy to C40101)
Protocol Number: C70301 (substudy to C40101)
Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Node-Negative Breast Cancer
Trial Type: Clinical
Z1071Protocol Document: Z1071
Protocol Number: Z1071
Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis
Trial Type: Clinical
Cancer ControlCALGB 170601Protocol Document: CALGB 170601
Protocol Number: CALGB 170601
Phase III Double-Blind Trial of Oral Duloxetine for Treatment of Pain Associated with Chemotherapy-Induced Peripheral Neuropathy
Trial Type: Clinical
CALGB 70604Protocol Document: CALGB 70604
Protocol Number: CALGB 70604
Randomized Phase III Study of Standard Dosing vs. Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Trial Type: Clinical
N07C2Protocol Document: N07C2
Protocol Number: N07C2
The Use of Wisconsin Ginseng (panax quinquefoliuis) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Trial Type: Clinical
N08C1 B closed; C minority only - A/D generalProtocol Document: N08C1 B closed; C minority only - A/D general
Protocol Number: N08C1 B Closed; C minority only - A/D general
Paclitaxel-Associated Acute Pain Syndrome Natural History Study
Trial Type: Clinical
N08C3Protocol Document: N08C3
Protocol Number: N08C3
Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Preventino of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly Emetogenic Chemotherapy
Trial Type: Clinical
N08C7 Closed to general - open minority onlyProtocol Document: N08C7 Closed to general - open minority only
Protocol Number: N08C7 closed to general - open minority only
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Flaxseed for Treatment of Hot Flashes
Trial Type: Clinical
RC08C6Protocol Document: RC08C6
Protocol Number: RC08C6
White Wine for Appetite Loss: A Randomized, Controlled Trial
Trial Type: Clinical
RC08CC Protocol Document: RC08CC
Protocol Number: RC08CC
The Use of Calcium and Magnesium for Prevention of Ixabepilone Induced Peripheral Neuropathy: A Phase III Double-Blind, Placebo-Controlled Study
Trial Type: Clinical
S0702Protocol Document: S0702
Protocol Number: S0702
A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment
Trial Type: Clinical
WFU 97405 SuspendedProtocol Document: WFU 97405 Suspended
Protocol Number: WFU 97405
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men with Prostate Cancer
Trial Type: Clinical
N04C2 Protocol Document: N04C2
Protocol Number: N04C2
An Exploratory, Randomzied, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR Depot) for Symptomatic Ascites in Cancer Patients
Trial Type: Clinical
GastrointestinalE5202 Protocol Document: E5202
Protocol Number: E5202
Randomized Phase III Study Comparing 5FU, Leucovorin and Oxaliplatin vs. 5FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Marks
Trial Type: Clinical
S0809Protocol Document: S0809
Protocol Number: S0809
Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Trial Type: Clinical
N0346Protocol Document: N0346
Protocol Number: N0346
Phase II Trial of Celecoxib and Capecitabine Combined with Pelvic Irradiation as Neoadjuvant Treatment of Stage II or III Adenocarcinoma of the Rectum
Trial Type: Clinical
RC0948Protocol Document: RC0948
Protocol Number: RC0948
The Oncotype DX Colon Cancer Assay for Stage II Colon Carcinoma: Does it Impact Physician Adjuvant Treatment Decision Making and Patient Satisfaction.
Trial Type: Clinical
N0747Protocol Document: N0747
Protocol Number: N0747
Randomzied Phase II Trial of Sunitinib Plus Capecitabine vs. Capecitabine Alone (With the Potential for Cross Over) for Elderly and/or Poor Performance Status Patients with Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Trial Type: Clinical
N0849 SUSPENDEDProtocol Document: N0849 SUSPENDED
Protocol Number: N0849
Randomized Phase II Trial of Extended Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, or Gastric Cardia
Trial Type: Clinical
CALGB 80802Protocol Document: CALGB 80802
Protocol Number: CALGB 80802
Phase III Randomized Study of Sorafenib (IND 69896, NSC 724772) Plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)
Trial Type: Clinical
CALGB 80405 Protocol Document: CALGB 80405
Protocol Number: CALGB 80405
Phase III Trial of Irinotecan/5FU/Leucovorin or Oxaliplatin/5FU/Leucovorin with Bevacizumab, or Cetuximab (C225) or With The Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Trial Type: Clinical
S0600 Protocol Document: S0600
Protocol Number: S0600
Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab With or Without Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who Have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX, or XELOX
Trial Type: Clinical
E3205 Protocol Document: E3205
Protocol Number: E3205
Phase II Trial of Cetuximab Plus Cisplatin, 5 FU and Radiation in Immunocompetent Patients with Anal Carcinoma
Trial Type: Clinical
N0543Protocol Document: N0543
Protocol Number: N0543
Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Trial Type: Clinical
GenitourinaryCALGB 90401Protocol Document: CALGB 90401
Protocol Number: CALGB 90401
Randomized Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with and without Bevacizumab in Men with Hormone Refractory Prostate Cancer
Trial Type: Clinical
R0232Protocol Document: R0232
Protocol Number: R0232
Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma
Trial Type: Clinical
R0526Protocol Document: R0526
Protocol Number: R0526
A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy.
Trial Type: Clinical
R0534Protocol Document: R0534
Protocol Number: R0534
Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (Sport) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy
Trial Type: Clinical
R0815Protocol Document: R0815
Protocol Number: R0815
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
Trial Type: Clinical
R0831 SUSPENDEDProtocol Document: R0831 SUSPENDED
Protocol Number: R0831 SUSPENDED
Randomized, Double-Blind, Placebo-Controlled Phase III Trial To Evaluate the Effectiveness of a Phosphodiesterate 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated with Radiotherapy for Prostate Cancer
Trial Type: Clinical
E2804 Adv. MRI Image - closedProtocol Document: E2804 Adv. MRI Image - closed
Protocol Number: E2804 Adv. MRI Image - closed
A Randomized Phase II Study of VEGF, RAF Kinase, and MTOR Combination GTargeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma
Trial Type: Clinical
E2805 Study to close 9/1/10Protocol Document: E2805 Study to close 9/1/10
Protocol Number: E2805
Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib vs. Sorafenib vs. Placebo in Patients with Resected Renal Cell Carcinoma
Trial Type: Clinical
CALGB 90601Protocol Document: CALGB 90601
Protocol Number: CALGB 90601
Randomized, Double-Blind, Phase III Study Comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma
Trial Type: Clinical
Head and NeckE1308 Protocol Document: E1308
Protocol Number: E1308
Phase II Trial of Inductino Chemotherapy Followed by Cetuximab with Low Dose vs. Standard Dose IMRT in Patients with HPV-Associated Resectable Squamous Cell Carcinoma for the Oropharynx
Trial Type: Clinical
R0537 Phase II ClosedProtocol Document: R0537 Phase II Closed
Protocol Number: R0537 Phase II Closed
Phase II/III Study Comparing Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) vs. Pilocarpine in Treating Early Radiation-Induced Xerostomia
Trial Type: Clinical
R0920 Protocol Document: R0920
Protocol Number: R0920
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Trial Type: Clinical
HematologyE2905 Protocol Document: E2905
Protocol Number: E2905
Randomized Phase III Trial Comparing the Frequency of MajorErythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low or Intermediate - 1 Risk MDS and Symptomatic Anemia
Trial Type: Clinical
RC0783 Protocol Document: RC0783
Protocol Number: RC0783
Randomzied Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab With or Without Current Avastin for Previouly Untreated B-Chronic Lymphocytic Leukemia (CLL)
Trial Type: Clinical
S0816 - Special Regulatory with AG Mednet SystemProtocol Document: S0816 - Special Regulatory with AG Mednet System
Protocol Number: S0816 - Special Regulatory with AG Mednet System
Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging
Trial Type: Clinical
S0777 Protocol Document: S0777
Protocol Number: S0777
Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) vs. Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD), for Induction in Patients with Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant
Trial Type: Clinical
LungS0220Protocol Document: S0220
Protocol Number: S0220
A PHASE II TRIAL OF INDUCTION CHEMORADIOTHERAPY WITH CISPLATIN/ETOPOSIDE FOLLOWED BY SURGICAL RESECTION, FOLLOWED BY DOCETAXEL, FOR NON-SMALL CELL LUNG CANCER INVOLVING THE SUPERIOR SULCUS (PANCOAST TUMORS)
Trial Type: Clinical
CALGB 30607Protocol Document: CALGB 30607
Protocol Number: CALGB 30607
Randomized Phase III, Placebo-Controlled Trial of Sunitinib as Maintenance therapy in Non-Progressing Patients Following an Initial Foru Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer
Trial Type: Clinical
E1505Protocol Document: E1505
Protocol Number: E1505
Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB - IIIA Non-Small Cell Lung Cancer
Trial Type: Clinical
E4508 Protocol Document: E4508
Protocol Number: E4508
Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-Small Cell Lung Cancer Patients Who Will Not Receive Bevacizumab-Based Therapy
Trial Type: Clinical
N0821 Protocol Document: N0821
Protocol Number: N0821
A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Non-Squamous, Non-Small Cell Lung Cancer Evaluating Efficacy and Tolerability in Elderly Patients (age greater than 70 years) with Good Performance Status (PS less than 2)
Trial Type: Clinical
R0617 Protocol Document: R0617
Protocol Number: R0617
A Rnaodmized Phase III Comparison of Standard Dose (60 Gy) vs. High Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer
Trial Type: Clinical
R0813Protocol Document: R0813
Protocol Number: R0813
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer in Medically Inoperable Patients
Trial Type: Clinical
R0915Protocol Document: R0915
Protocol Number: R0915
Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage 1 Peripheral Non-Small Cell Lung Cancer
Trial Type: Clinical
S0424Protocol Document: S0424
Protocol Number: S0424
Molecular Epidemiology Case-Series Study of Non-Small CellLung Cancer in Smoking and Non-Smoking Women and Men
Trial Type: Clinical
S0819 Protocol Document: S0819
Protocol Number: S0819
Randomized Phase III Study Comapring Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer
Trial Type: Clinical
E1508 Protocol Document: E1508
Protocol Number: E1508
Randomized Phase II Study of Cisplatin and Etoposide in Combination with Either Hedgehog Inhibitor GDC-0449 or IG-1R Monoclonal Antibody IMC-A12 for Patients with Extensive Stage Small Cell Lung Cancer
Trial Type: Clinical
N0923Protocol Document: N0923
Protocol Number: N0923
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Induction Regimens of Cytoreductive Chemotherapy for Patients with Extensive Stage Small Cell Lung Carcinoma
Trial Type: Clinical
R0937Protocol Document: R0937
Protocol Number: R0937
Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer
Trial Type: Clinical
MelanomaE1697 Protocol Document: E1697
Protocol Number: E1697
Randomized Study of Four Weeks High Dose IFN-12B In Stage IIA Melanoma
Trial Type: Clinical
N0879 SUSPENDEDProtocol Document: N0879 SUSPENDED
Protocol Number: N0879
Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or Without Everolimus for Therapy of Metastatic Malignant Melanoma
Trial Type: Clinical
Patient Satisfaction SurveyN0392 - NCCTG Companion StudyProtocol Document: N0392 - NCCTG Companion Study
Protocol Number: N0392 - NCCTG Companion Study
Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical trials
Trial Type: Clinical
Pharmaceutical20062080Protocol Document: 20062080
Protocol Number: 20062080
Phase 2, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Trial Type: Clinical
AVF3991 - NSCL onlyProtocol Document: AVF3991 - NSCL only
Protocol Number: AVF3991 - NSCL only
An Observational Study of Avastin in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer, Locally Advanced or Metastatic Non-Small Cell Lung (Excluding Predominant Squamous Cell Histology, or Locally Recurrent of Metastatic Breast Cancer)
Trial Type: Clinical
H8K-MC-JZAO Call TCOPProtocol Document: H8K-MC-JZAO Call TCOP
Protocol Number: H8K-MC-JZAO
Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma
Trial Type: Clinical
20060392 Call TCOPProtocol Document: 20060392 Call TCOP
Protocol Number: 20060392
Prospective Multi-National Observational Study to Assess Health Resource Utilization Associated with Skeletal Related Events in Patients with Bone Metastases Secondary to Breast, Prostate, or Lung Cancer, or Multiple Myeloma.
Trial Type: Clinical
Unknown PrimaryN0871Protocol Document: N0871
Protocol Number: N0871
Phase II Study of Carboplatin, Paclitaxel and Everolimus in Previously Untreated Patients with Measurable Disease with Cancer of Unknown Primary
Trial Type: Clinical
|
